Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer

Table 2 Evaluation of risks for adenoma

	Criteria	(Case/Cont)		Univariate analysis OR (95% CI)	P value	Multivariate analysis OR (95% CI)	P value
		Low	High
BMI (kg/m2)	< 22.5, ≥ 22.5	18/14	29/10	2.256 (0.828-6.145)	0.112	1.432 (0.434-4.729)	0.556
BP-S (mmHg)	< 120, ≥ 120	14/14	33/12	1.030 (0.998-1.074)	0.073	1.576 (0.463-5.370)	0.467
BP-D (mmHg)	< 80, ≥ 80	32/18	15/8	1.055 (0.375-2.967)	0.920
Glucose (mg/dL)	< 100, ≥ 100	27/14	19/10	0.992 (0.976-1.008)	0.328
Insulin (ng/mL)	< 4.5, ≥ 4.5	12/12	35/14	1.033 (0.989-1.091)	0.249
HOMA-IR	< 2, ≥ 2	27/15	19/9	1.173 (0.426-3.232)	0.758
T-cho (mg/dL)	< 180, ≥ 180	19/13	27/10	1.005 (0.992-1.019)	0.449
TG (mg/dL)	< 120, ≥ 120	25/19	21/4	3.990 (1.173-13.570)	0.027a	2.713 (0.707-10.410)	0.146
hsCRP (ng/mL)	< 500, ≥ 500	20/16	27/10	2.160 (0.811-5.750)	0.123
IGF-1/IGFBP-3	< 60, ≥ 60	29/15	18/11	0.846 (0.319-2.245)	0.074
Adiponectin (μg/mL)	< 11, ≥ 11	40/12	7/14	6.667 (2.190-20.300)	0.001b	5.762 (1.683-19.739)	0.005b
Leptin (ng/mL)	< 3, ≥ 3	17/13	30/13	1.765 (0.668-4.665)	0.252
Resistin (ng/mL)	< 42, ≥ 42	17/13	30/13	1.184 (0.524-3.642)	0.514

OR: Odds ratio; CI: Confidence interval; TG: Triglyceride; T-cho: Total cholesterol; hs-CRP: High sensitivity C-reactive protein; HOMA-IR: Homeostatic model assessment of insulin resistance; IGF-1/IGFBP-3: Ratio of insulin-like growth factor-1 and IGF binding protein-3; Cont: Numbers of control persons; Case: Numbers of patients. The OR (High vs Low) was evaluated by univariate and multivariate logistic regression analysis. Only the OR of adiponectin was inversely evaluated (Low vs High). Multivariate analysis included age, BMI, BP-S, TG, and adiponectin.

^aP < 0.05,

^bP < 0.01.